| Anti-CTLA-4 therapies |
| Shift in intra-tumoural CD8/Treg ratio [34] |
| Increase in circulating ICOS+ CD4+ effector T cells [41] |
| Increase in Granzyme B+ CD8+ T cells [42] |
| Rise in absolute lymphocyte count [48,49] |
| Baseline FoxP3 and IDO expression [44] |
| Baseline ‘immune active’ tumour microenvironment [66] |
| CTLA-4+ CD4+ effector T cells [49] |
| EOMES+ CD8+ T cells [50] |
| Baseline circulating monocytic MDSCs [51] |
| Reduction in monocytic MDSCs in periphery and tumour [52] |
| Baseline serum VEGF [58] |
| Baseline serum LDH [53] |
| Maintenance of high frequency T cell clones in periphery [68] |
| Neo-antigenic repertoire [71] |
| Anti-PD-1/-PD-L1 therapies |
| Tumour PD-L1 expression [3,6,8,12,13,84-86] |
| Tumour infiltrating immune cell PD-L1 expression [83] |
| Increased tumouralIFNγ, Granzyme-A, CD8, EOMES and CX3CL1 gene expression [90] |
| Increased CD8+PD-1+PD-L1+ cell density within tumour and at invasive tumour margin [84] |
| Increased clonality and reduced diversity of intra-tumoural T cell repertoire [84] |
| Higher somatic mutational burden and neo-antigenic repertoire [92] |
